Calypso Biotech, a clinical-stage spin-off from Merck Serono, develops therapeutic biologics that targets Interleukin-15 (IL-15). Its lead product is a best-in-class anti-IL-15 antibody CALY-002 for auto-immune diseases, currently in Phase 1 trial.

Cooperation possibilities

Calypso Biotech is willing to enter into collaboration(s) to support the pharmacological validation of CALY-002 in translational medicine experiments, develop biomarkers, and support IND-enabling studies, including manufacturing.

Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland
Key business